-
Protoporphyrin IX Workflows for Heme and Photodynamic Resear
2026-09-20
Build controlled assays around Protoporphyrin IX for heme formation, light-triggered biology, and mechanistic ferroptosis studies. This guide separates photodynamic effects from iron-handling pathways with practical formulation, illumination, and troubleshooting workflows.
-
EZH2 Inhibition in HPV-Associated Cervical Cancer
2026-09-19
A 2025 study evaluates EPZ6438 and ZLD1039 as EZH2 inhibitors in HPV-positive and HPV-negative cervical cancer models. The findings connect EZH2 suppression with reduced proliferation, apoptosis, G0/G1 arrest, decreased HPV16 E6/E7 expression, and restoration of p53, Rb, and epithelial markers, while identifying greater activity of EPZ6438 in HPV-positive cells.
-
DiscoveryProbe Immunology/Inflammation Compound Library
2026-09-18
Turn a curated 295-compound collection into multiparametric evidence for immune activation, suppression, proliferation, and toxicity. This PBMC flow-cytometry workflow links phenotypic inflammation screening with inflammation target validation and mechanism-focused follow-up.
-
Verapamil HCl: Applied Calcium Signaling Workflows
2026-09-18
Verapamil HCl is an L-type calcium channel blocker for dissecting calcium-dependent signaling, apoptosis, drug accumulation, and inflammation. This workflow-focused guide shows how to design myeloma combination assays, interpret transporter-related effects, and extend findings into an arthritis inflammation model without overclaiming mechanism.
-
HyperScript™ Reverse Transcriptase for RNA-to-cDNA
2026-09-17
HyperScript™ Reverse Transcriptase supports demanding RNA-to-cDNA workflows when secondary structure, long transcripts, or limited template abundance can compromise routine reverse transcription. Its thermal stability and reduced RNase H activity make it a practical choice for qPCR studies of adipose remodeling, including Netrin-1, PPARγ, and Wnt/β-catenin signaling.
-
C34: A TLR4 Inhibitor for Assay Translation
2026-09-17
C34 is a selective TLR4 inhibitor for dissecting LPS-driven inflammatory signaling in macrophages, enterocytes, and translational neuroinflammation models. This guide explains how to use C34 as a pathway-control reagent, interpret evidence from microglial studies, and distinguish target-level conclusions from broader anti-inflammatory effects.
-
Verapamil Targets Txnip in Osteoporosis
2026-09-16
The reference study presents verapamil as a repurposing candidate for osteoporosis by linking TXNIP genetic variation and drug-mediated Txnip suppression to bone remodeling. Its combination of human association data, cell-based assays, transcriptomics, and ovariectomy-mouse experiments identifies distinct ChREBP-Txnip mechanisms in osteoclasts and osteoblasts, while remaining preclinical.
-
Resveratrol, CAFs, and Breast Cancer Hybrid Organoids
2026-09-16
A 2025 study used patient-derived breast cancer organoids combined with cancer-associated fibroblasts to model microenvironment-mediated drug protection. Resveratrol inhibited organoid growth, removed the fibroblast-associated growth advantage, and reduced CAF-associated VCAN and TGF-β expression, supporting organoid co-culture as a more informative context for proliferation studies.
-
Catalpol: A Neurovascular Unit Research Framework
2026-09-15
Catalpol, also known as Catalpinoside, offers a multi-pathway framework for studying neurovascular unit recovery after ischemic injury. This article translates key preclinical findings into practical assay, dosing, and interpretation decisions while distinguishing mechanistic evidence from broader disease-model applications.
-
From LDHA Mechanism to Stronger RCC Evidence
2026-09-15
Gingerenone A offers a compelling metabolic strategy for restoring sunitinib sensitivity in renal cell carcinoma. This thought-leadership analysis explains how rigorous western blot chemiluminescence detection can connect LDHA, lactate, HIF-1α, and angiogenic signaling to a more defensible translational evidence chain.
-
Catalpol: Mechanisms and Preclinical Research
2026-09-14
Catalpol, also called Catalpinoside in some research sources, is a Rehmannia-derived iridoid glycoside with multi-pathway preclinical activity. Its strongest research value is as a mechanism-oriented tool for neuroprotection research, ischemic stroke models, osteoporosis animal models, and inflammation-linked organ injury—not as a clinically established therapy.
-
Protease Inhibitor Cocktail: MS-SAFE Extraction
2026-09-14
Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) helps limit endogenous proteolysis during cell and tissue extraction, with an AEBSF-free formulation intended for mass spectrometry workflows. It is suitable for crude lysates and biochemical sample preparation, but it should not be treated as a universal inhibitor, a complete phosphatase-inhibitor system, or a validated live-cell treatment without additional testing.
-
Arachidonic Acid for Reliable Cell Assays
2026-09-13
A practical, scenario-based guide to using Arachidonic Acid (SKU C4223) in cell viability, proliferation, and cytotoxicity workflows. It addresses solvent compatibility, concentration design, pathway interpretation, vendor selection, and evidence limitations for reproducible lipid-signaling experiments.
-
Rucaparib, Splicing, and PARP Sensitivity
2026-09-12
Rucaparib (AG-014699, PF-01367338) offers a practical framework for studying how DNA repair state, radiation response, transporter biology, and spliceosome regulation shape PARP inhibitor sensitivity. Integrating product intelligence with a 2024 Nature Communications study on SmD2 acetylation, this article outlines translational experiments that connect HCC spliceosome biology with prostate cancer radiosensitization while distinguishing evidence from forward-looking hypotheses.
-
Isochlorogenic Acid A: From Molecule to Wound Repair
2026-09-11
Isochlorogenic acid A is moving from natural-product discovery toward formulation-led wound-repair research. This article examines its chemistry, Fe(III)-coassembled hydrogel evidence, experimental controls, translational limits, and strategic next steps for reproducible anti-infection, immunology, and inflammation research.